MNCs Discuss China’s Pharmaceutical Market Outlook
This article was originally published in PharmAsia News
Executive Summary
The recent 2008 new pharmaceutical business development forum in Qingdao, China, organized by Pfizer Investment, aimed to provide a platform for exchanging knowledge and analyses for the drug community. Pharmaceutical giants such as Xian-Janssen, Johnson & Johnson, Bayer and Novartis shared their business development strategies and market outlook for China, with participation from McKinsey and PricewaterhouseCoopers. Besides continuing to speed up new drug development, launch and patent application, MNCs are shifting from the previous tradition of setting up plants for production, to pursuing mergers and acquisitions to build a firm foothold in the local market. All seek new collaborative approaches to tap the vast potential of the country, according to forum participants. (Click here for more - Chinese Language)
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.